Genistein effect on cognition in prodromal Alzheimer's disease patients. The GENIAL clinical trial
- PMID: 36329553
- PMCID: PMC9635167
- DOI: 10.1186/s13195-022-01097-2
Genistein effect on cognition in prodromal Alzheimer's disease patients. The GENIAL clinical trial
Abstract
Background: Delaying the transition from minimal cognitive impairment to Alzheimer's dementia is a major concern in Alzheimer's disease (AD) therapeutics. Pathological signs of AD occur years before the onset of clinical dementia. Thus, long-term therapeutic approaches, with safe, minimally invasive, and yet effective substances are recommended. There is a need to develop new drugs to delay Alzheimer's dementia. We have taken a nutritional supplement approach with genistein, a chemically defined polyphenol that acts by multimodal specific mechanisms. Our group previously showed that genistein supplementation is effective to treat the double transgenic (APP/PS1) AD animal model.
Methods: In this double-blind, placebo-controlled, bicentric clinical trial, we evaluated the effect of daily oral supplementation with 120 mg of genistein for 12 months on 24 prodromal Alzheimer's disease patients. The amyloid-beta deposition was analyzed using 18F-flutemetamol uptake. We used a battery of validated neurocognitive tests: Mini-Mental State Exam (MMSE), Memory Alteration Test (M@T), Clock Drawing Test, Complutense Verbal Learning Test (TAVEC), Barcelona Test-Revised (TBR), and Rey Complex Figure Test.
Results: We report that genistein treatment results in a significant improvement in two of the tests used (dichotomized direct TAVEC, p = 0.031; dichotomized delayed Centil REY copy p = 0.002 and a tendency to improve in all the rest of them. The amyloid-beta deposition analysis showed that genistein-treated patients did not increase their uptake in the anterior cingulate gyrus after treatment (p = 0.878), while placebo-treated did increase it (p = 0.036). We did not observe significant changes in other brain areas studied.
Conclusions: This study shows that genistein may have a role in therapeutics to delay the onset of Alzheimer's dementia in patients with prodromal Alzheimer's disease. These encouraging results indicate that this should be followed up by a new study with more patients to further validate the conclusion that arises from this study.
Trial registration: NCT01982578, registered on November 13, 2013.
Keywords: Amyloid-beta cingulate gyrus; Cognitive impairment; Phytoestrogens; Soy isoflavones.
© 2022. The Author(s).
Conflict of interest statement
This was supported exclusively by public funds in Spain and was performed in two public hospitals in Valencia. No private industry support must be disclosed. Genistein-containing pills were bought from commercially available sources that were distributed in the chemist shop system in Spain. Moreover, no non-financial conflicts of interest exist for any of the authors.
Figures
Similar articles
-
[Effects of the use of 17 β-estradiol and genistein in Alzheimer's disease in women with menopause].Rev Esp Geriatr Gerontol. 2021 Jul-Aug;56(4):236-240. doi: 10.1016/j.regg.2021.04.005. Epub 2021 Jun 8. Rev Esp Geriatr Gerontol. 2021. PMID: 34112537 Review. Spanish.
-
Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.N Engl J Med. 2019 Apr 11;380(15):1408-1420. doi: 10.1056/NEJMoa1812840. N Engl J Med. 2019. PMID: 30970186 Free PMC article. Clinical Trial.
-
Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease.Neuroimage Clin. 2019;22:101786. doi: 10.1016/j.nicl.2019.101786. Epub 2019 Mar 19. Neuroimage Clin. 2019. PMID: 30921610 Free PMC article.
-
Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.Lancet Neurol. 2018 Apr;17(4):335-346. doi: 10.1016/S1474-4422(18)30029-2. Epub 2018 Feb 27. Lancet Neurol. 2018. PMID: 29500152
-
Metal protein attenuating compounds for the treatment of Alzheimer's dementia.Cochrane Database Syst Rev. 2012 May 16;5(5):CD005380. doi: 10.1002/14651858.CD005380.pub4. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2014 Feb 21;(2):CD005380. doi: 10.1002/14651858.CD005380.pub5. PMID: 22592705 Free PMC article. Updated. Review.
Cited by
-
Flavonoids as Potential Therapeutics Against Neurodegenerative Disorders: Unlocking the Prospects.Neurochem Res. 2024 Aug;49(8):1926-1944. doi: 10.1007/s11064-024-04177-x. Epub 2024 Jun 1. Neurochem Res. 2024. PMID: 38822985 Review.
-
Role of Epigenetic Modulation in Neurodegenerative Diseases: Implications of Phytochemical Interventions.Antioxidants (Basel). 2024 May 15;13(5):606. doi: 10.3390/antiox13050606. Antioxidants (Basel). 2024. PMID: 38790711 Free PMC article. Review.
-
A Review of Recent Advances in the Management of Alzheimer's Disease.Cureus. 2024 Apr 16;16(4):e58416. doi: 10.7759/cureus.58416. eCollection 2024 Apr. Cureus. 2024. PMID: 38756263 Free PMC article. Review.
-
Isoflavonoid metabolism in leguminous plants: an update and perspectives.Front Plant Sci. 2024 Feb 9;15:1368870. doi: 10.3389/fpls.2024.1368870. eCollection 2024. Front Plant Sci. 2024. PMID: 38405585 Free PMC article. Review.
-
Phenolic Compounds of Therapeutic Interest in Neuroprotection.J Xenobiot. 2024 Feb 6;14(1):227-246. doi: 10.3390/jox14010014. J Xenobiot. 2024. PMID: 38390994 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical